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Abstract
Rationale Synaptic memory consolidation is thought to rely
on catecholaminergic signaling. Eventually, it is followed by
systems consolidation, which embeds memories in a neocor-
tical network. Although this sequence was demonstrated in
rodents, it is unclear how catecholamines affect memory con-
solidation in humans.
Objectives Here, we tested the effects of catecholaminergic
modulation on synaptic and subsequent systems consolida-
tion. We expected enhanced memory performance and in-
creased neocortical engagement during delayed retrieval.
Additionally, we tested if this effect was modulated by indi-
vidual differences in a cognitive proxy measure of baseline
catecholamine synthesis capacity.
Methods Fifty-three healthy males underwent a between-sub-
jects, double-blind, placebo-controlled procedure across
2 days. On day 1, subjects studied and retrieved object-
location associations and received 20 mg of methylphenidate
or placebo. Drug intake was timed so that methylphenidate
was expected to affect early consolidation but not encoding
or retrieval. Memory was tested again while subjects were
scanned three days later.
Results Methylphenidate did not facilitate memory perfor-
mance, and there was no significant group difference in
activation during delayed retrieval. However, memory repre-
sentations differed between groups depending on baseline cat-
echolamines. The placebo group showed increased activation
in occipito-temporal regions but decreased connectivity with
the hippocampus, associated with lower baseline catechol-
amine synthesis capacity. The methylphenidate group showed
stronger activation in the postcentral gyrus, associated with
higher baseline catecholamine synthesis capacity.
Conclusions Altogether, methylphenidate during early con-
solidation did not foster long-term memory performance, but
it affected retrieval-related neural processes depending on in-
dividual levels of baseline catecholamines.
Keywords Ritalin . Dopamine . Norepinephrine . Synaptic
tagging and capture . Systems consolidation . fMRI
Introduction
Memories for some experiences quickly fade while others
persist for a lifetime. The process that converts and integrates
initially fragile memories into a stable engram is referred to as
memory consolidation (Dudai 2004; Squire et al. 2015).
Foremost, consolidation involves changes at the synaptic lev-
el. According to the synaptic tagging and capture hypothesis
(Frey and Morris 1997; and see Redondo and Morris 2011 for
a reformulation and review), the encoding of new information
triggers synaptic long-term potentiation (LTP) that results in
neurochemical and structural alterations. Together, this creates
the potential for a long-lasting synaptic change. The memory
trace, however, is only stabilized and stored in long-term
memory if these cellular events are accompanied by the syn-
thesis of plasticity-related proteins (PRPs; Moncada and Viola
2007; Bekinschtein et al. 2008; Ballarini et al. 2009; Moncada
et al. 2011). This cascade of events critically depends on the
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influx of catecholamines, such as dopamine (DA) and norepi-
nephrine (NE), into the hippocampus (or other task-relevant
brain regions; Ballarini et al. 2009). Blockade of the catechol-
aminergic transmitter system after encoding was shown to
prevent long-term memory stabilization (Moncada and Viola
2007; Rossato et al. 2009; Moncada et al. 2011) but not im-
mediate memory (Bethus et al. 2010). Facilitation of catechol-
amine signaling, on the other hand, was found to enhance
memory persistence (Moncada and Viola 2007; Rossato
et al. 2009; Wang et al. 2010; Moncada et al. 2011;
McNamara et al. 2014). Evidence for the role of the synaptic
tagging and capture hypothesis in long-term memory forma-
tion, however, mostly stems from evidence in rodents (but see
Wetzel et al. 1981; Izquierdo et al. 2008). Therefore, we in-
vestigated if catecholamine modulation after encoding facili-
tated long-term memory stabilization in humans.
After initial synaptic modifications (mostly investigated) in
the hippocampus, memories increasingly depend on neocorti-
cal structures as consolidation progresses (Marr 1970;
Frankland and Bontempi 2005; Takashima et al. 2006;
Takehara-Nishiuchi and McNaughton 2008; Lesburguères
et al. 2011). Typically, successful retrieval of consolidated
memories involves the medial prefrontal and posterior cingu-
late cortex, the angular gyrus, and posterior representational
regions that code for specific features of the task material at
hand (Rugg and Vilberg 2012; Wagner et al. 2015; King et al.
2015). Here, we hypothesized that catecholamine modulation
would not only foster synaptic but also subsequent systems
consolidation.
A stimulant that blocks both DA and NE reuptake (Volkow
et al. 2001; Hannestad et al. 2010) and thereby increases cat-
echolamine availability in the synaptic cleft is methylpheni-
date (MPH; Ritalin®). MPH is widely prescribed to alleviate
symptoms of inattention and hyperactivity in attention-deficit/
hyperactivity disorder (Faraone and Buitelaar 2010; Wigal
et al. 2011) and is used by healthy individuals to improve
academic performance (Greely et al. 2008; Smith and Farah
2011). Aside from its enhancing effects in multiple cognitive
domains (see Linssen et al. 2014b for a review), few studies
have investigated the effects of MPH on memory (Wetzel
et al. 1981; Izquierdo et al. 2008; Linssen et al. 2012;
Linssen et al. 2014a). For example, MPH given before
encoding was found to facilitate the delayed but not the im-
mediate recall of word lists (Linssen et al. 2012; Linssen et al.
2014a). However, MPH likely boosted attention at encoding,
making it difficult to delineate its effects on post-encoding
consolidation. Thus, we asked if catecholamine modulation
by MPH after encoding would promote the synaptic and sub-
sequent systems consolidation of associative memories.
The present study spanned across 2 days that were 72 h
apart (Fig. 1a). After studying object-location associations on
day 1 (comparable to van Buuren et al. 2014), subjects re-
ceived a single, oral dose of either MPH or placebo and were
tested immediately for their initial memory (immediate recall
test). Based on the pharmacological profile of MPH (Swanson
and Volkow 2003), we expected a drug effect on brain func-
tion after the immediate recall test, during early consolidation,
affecting memory 3 days later. Up-regulation of catecholamin-
ergic signaling should then foster LTP and PRP release and
promote synaptic and subsequent systems consolidation (Frey
and Morris 1997; Frankland and Bontempi 2005). Long-term
associative memory was tested again after about 72 h (day 4)
during the delayed recall test while subjects were scanned
using functional MRI.
We expected that MPH during early consolidation would
stabilize initially fragile memories that would otherwise decay
and enhance long-term associative memory performance in
the MPH compared to the placebo group. This should be
paralleled by increased engagement of neocortical regions
during correct memory retrieval in MPH relative to placebo
subjects, including medial prefrontal and posterior cingulate
regions, the angular gyrus, and posterior representational
areas. Additionally, the effects of catecholaminergic drugs
on cognitive performance were previously shown to depend
on individual working memory capacity which serves as a
proxy for baseline catecholamine synthesis capacity (Cools
et al. 2008; Landau et al. 2009). While task performance in
subjects with low working memory capacity typically benefits
from the administration of catecholaminergic stimulants
(Mehta et al. 2000; Gibbs and D’Esposito 2005), it can have
detrimental effects in subjects with high working memory
capacity (Kimberg et al. 1997). Thus, we stratified our behav-
ioral and neuronal effects with working memory capacity to
take into account individual differences in baseline catechol-
amine synthesis capacity.
Materials and methods
Subjects
Sixty healthy males (mean = 23 years, age range = 18–
31 years) volunteered for this study and provided written
informed consent prior to participation. A total of seven
subjects were excluded from the study: three subjects did
not return after the intake procedure (Materials and
methods, Intake procedure), one subject did not perform
the task as instructed, two subjects were excluded due to
a mistake by one of the experimenters, and one subject
was excluded due to an incidentally found brain abnor-
mality. This left 53 subjects (mean = 23 years, age
range = 18–31 years) for the final analysis. The experi-
mental protocol was reviewed and approved by the insti-
tutional review board (CMO Region Arnhem-Nijmegen,
The Netherlands; registration number 2014/289).
Recruitment took place via the subject database of the
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Radboud University (radboud.sona-systems.com) and flyers.
Subjects received monetary compensation for participation.
Intake procedure
All subjects underwent an intake procedure in the form of a
personal interview. This consisted of a medical screening to
determine whether the subject met all of the inclusion and
none of the exclusion criteria. Blood pressure and heart rate
were measured using a digital blood pressure monitor (Omron
Healthcare Europe B.V., The Netherlands). Inclusion criteria
were as follows: age between 18 and 35 years, normal or
corrected-to-normal vision, no current disease, male, and
right-handed. Exclusion criteria were as follows: (history of)
psychiatric, neurological, or endocrine treatment; autonomic
failure (e.g., vasovagal reflex syncope); (history of) clinically
significant hepatic, cardiac, obstructive respiratory, renal, ce-
rebrovascular, metabolic, or pulmonary disease; family
history of sudden death or ventricular arrhythmia; (history
of) epilepsy; (history of) drug (opiates, LSD, (meth-) amphet-
amines, cocaine, solvents, barbiturates) or alcohol depen-
dence; family history of schizophrenia or bipolar disorder;
current or past use of psychotropic medication; regular use
of corticosteroids; suicidality; diabetes; uncontrolled hyper-
tension (defined as diastolic blood pressure at rest
>95 mmHg or systolic blood pressure at rest >180 mmHg);
hypotension (defined as diastolic blood pressure <50 mmHg
or systolic blood pressure <95 mmHg, or resting pulse rate
<45 beats/min); abnormal hearing or (uncorrected) vision;
lactose intolerance; irregular sleep/wake rhythm (e.g., regular
nightshifts or cross-timeline travel); current use of oral medi-
cation aside from occasional use of Paracetamol®; any per-
sonal characteristics that make the subjects ineligible to enter
the MR scanner such as non-removable metallic objects in the
body, active implants (e.g., pacemaker, neurostimulator),
claustrophobia, head surgery, or metallic tattoos.
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Fig. 1 Study timeline and associativememory task. aDay 1 took place in
the behavioral laboratory where subjects arrived at ∼10 a.m. They then
studied and retrieved object-location associations and received 20 mg
methylphenidate or placebo (t = 0). Peak drug effects were expected after
the immediate recall test, during the waiting period (t = ∼110 min), where
subjects were allowed to relax and watched nature documentaries. Heart
rate (HR), blood pressure (BP), and mood (PANAS) were assessed at
three times throughout day 1. On day 4, subjects were tested for all
object-location associations inside the MR scanner (delayed recall test).
b During study trials (behavioral lab, day 1), object-location associations
were learned. First, subjects viewed the grid with all objects placed at
their correct locations for 1.5 min (not depicted in figure). This was
followed by five study cycles, each containing study trials for all
object-location associations. A trial started with the presentation of an
empty grid and the object, surrounded by a red frame (here in black), at
the bottom of the screen (cue, 3 s). As the frame turned green (here in
grey), a cursor (marked as black square) appeared randomly at one of the
four sides of the grid and the subject was required to indicate the correct
object-location association (response, 2 s; exemplary cursor trajectory is
marked as dashed line). If the correct object-location was selected, the
object was shown in that location. If an incorrect object-location was
selected (as illustrated), the cursor turned red (here black) and the object
was shown in its correct location (feedback, 3 s). cDuring the immediate,
as well as the delayed recall test, subjects were tested for their memory of
all object-location associations. The trial started with the presentation of
the empty grid and the object, surrounded by a black frame, at the bottom
of the screen (cue, 3 s). As the frame turned green (here in grey), the
cursor appeared randomly at one of the four sides of the grid, and the
subject was required, indicating the correct object-location association
(response, 2.5 s). The figure shows an example of a correct answer, and
the cursor trajectory is marked as a dashed line. After responding, the
cursor turned grey for the remaining response period (not shown), and no
feedback was provided. The next trial started after a variable inter-trial
interval (ITI; mean = 5 s, range = 2.5–7 s)
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The intake procedure lasted ∼30 min. The final checklist
was signed off by one of the experimenters (authors ICW,
MvB, or LB) and the responsible study physician (last author
GF). If the subject was eligible for study participation, day 1
was scheduled within 4 weeks after the intake procedure. This
was not possible for three subjects. For those, another intake
procedure was scheduled before the start of day 1.
Study procedure
The study consisted of a between-subjects, double-blind,
placebo-controlled procedure across 2 days. Day 1 took place
in the behavioral laboratory where subjects studied and re-
trieved 64 object-location associations (Materials and
methods, Associative memory task) and received either
20 mg MPH or placebo. They were again tested for all
object-location associations during a delayed recall test inside
the MR scanner about 72 h later (day 4; Fig. 1a).
Subjects arrived at ∼10 a.m. on day 1. They were tested in
the behavioral laboratory in groups of maximum three, but
seated in separated cubicles so that interactions were mini-
mized. First, we asked if subjects had refrained from alcohol,
other drugs, and medication within the 24 h prior to the start of
day 1, and if they had undergone a medical examination since
the intake procedure. Next, we asked if subjects had con-
sumed caffeinated drinks or had smoked in the morning. No
subject had to be excluded because of these restrictions.
Furthermore, subjects were instructed to have a light breakfast
1 h before arrival. If they had not done so, they were offered a
small snack consisting of breakfast cookies and water.
Subjects subsequently completed a set of questionnaires, in-
cluding the Behavioural Inhibition Scale/Behavioural
Activation Scale (BIS/BAS; Carver and White 1994), the
Barratt Impulsiveness Scale (Patton et al. 1995), and the
ADHD Rating Scale-IV (DuPaul et al. 1998) to assess base-
line levels of impulsivity and ADHD symptoms, respectively.
The Positive and Negative Affect Scale (PANAS; Watson
et al. 1988) was used to assess the current mood (t =
−45 min before drug intake). Next, heart rate and blood pres-
sure were measured, and subjects were instructed for the as-
sociative memory task and performed the study phase of the
task (Materials and methods, Associative memory task).
After the study phase and before the immediate recall test
of the associative memory task, subjects received one oral
capsule of 20 mg MPH or placebo in a double-blind, random-
ized fashion (t = 0 min; Materials and methods, Study medi-
cation, randomization, and un-blinding procedure). Following
intake, they then performed the immediate recall test
(Materials and methods, Associative memory task). Plasma
levels of MPH peak 1.5–2 h (tmax) after drug intake
(Swanson and Volkow 2003) and we therefore reasoned that
the tmax would be reached after the immediate recall test.
The pharmacological effects of MPH diminish with a half-
life of 2–3 h (Swanson and Volkow 2003). To control activity
during the consolidation window (i.e., no arousing activity
that could trigger the additional release of catecholamines)
and to secure the subjects’ well-being following drug intake,
subjects remained in the behavioral laboratory for ∼3.5 h after
completing the immediate recall test. During this period, they
were allowed to relax and watch nature documentaries from a
desk chair (Planet Earth, Life, BBC, 2009). Blood pressure,
heart rate, and mood measures (PANAS) were obtained t =
110 min after drug intake (i.e., ∼90 min after the immediate
recall test), as well as t = 230 min after drug intake (i.e., ∼3.5 h
after the immediate recall test), and subjects were allowed to
consume snacks (sandwiches, cookies, water) after the t =
110 min measurement. In total, the session on day 1 took
∼5 h. The responsible study physician (last author GF) was
on call within the building at all times during day 1.
After 72 h, subjects returned to the laboratory and were
placed in the MR scanner (day 4; day 4–day 1 difference:
mean = 72 h; range = 70–73 h). They received the task instruc-
tions and underwent a brief resting-state scan (11 min), a
structural scan during which they could practice using the
MR-compatible trackball (5 min), and the delayed recall test
of the associative memory task (Materials and methods,
Associative memory task). Lastly, we assessed the working
memory capacity outside the scanner (Materials and methods,
Working memory capacity), subjects were debriefed about the
purpose of the study, and were asked if they thought that they
had received MPH or placebo (BDo you think you received
methylphenidate or placebo? How sure are you (0–100)?^).
The session on day 4 took ∼1.5 h.
Associative memory task
The associative memory task consisted of a study phase (day
1) and twomemory tests (immediate recall test, day 1; delayed
recall test inside the MR scanner, day 4; Fig. 1a). On day 1,
subjects were instructed to memorize the locations of 64 dif-
ferent objects (Hemera Photo-Object database, Hemera
Technologies) that were placed on an 8 × 8 grid (see also
van Buuren et al. 2014). A trackball (Orbit Optical
Trackball, Kensington) was used to perform the task and sub-
jects first completed a short practice round for familiarization.
Following this, the study phase of the associative memory task
started and subjects viewed the grid with all objects placed at
their correct locations for 1.5 min. They then completed five
study cycles that each contained 64 trials to study all object-
location associations. A trial started with the presentation of
the empty grid and an object presented at the bottom of the
screen, surrounded by a red frame (3 s; Fig. 1b). As soon as the
frame turned green, a cursor appeared randomly at one of the
four sides of the grid (this random start position was imple-
mented to avoid motor preparation), and the correct object-
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location had to be indicated by scrolling to and clicking on the
respective location on the grid (2 s). After responding, feed-
back was provided on screen for 3 s plus the remaining re-
sponse period. If the incorrect location was selected, the frame
turned red and the object was displayed at the correct location.
If the correct card was selected, the object was shown at that
location. After each learning cycle, subjects received a short
break of 30 s, indicated by a fixation cross presented on the
computer screen and the next study cycle started. The study
phase took ∼45 min. Object-location pairings were random-
ized across subjects and the presentation order was random-
ized within study cycles.
The immediate recall test (day 1) took place shortly after the
study phase, immediately following the drug intake (Materials
and methods, Procedure). Subjects were tested for their memory
of all 64 object-location associations. Again, a trial started with
the presentation of the empty grid and an object placed at the
bottom of the computer screen, surrounded by a black frame (3 s;
Fig. 1c). As the frame turned green, a cursor appeared randomly
at one of the four sides of the grid and subjects had to indicate the
correct location of the object by scrolling to and clicking on the
grid location (2.5 s). After responding, no feedback was provid-
ed, but the cursor turned grey for the remaining response time
and the next trial started after a variable delay of 2.5–7.5 s
(mean = 5 s) during which an asterisk was presented on the
screen. A short break of 30 s was given every 16 trials. Trial
presentation was randomized across subjects and the immediate
test lasted ∼15 min.
The delayed recall test (day 4, inside the MR scanner) was
identical to the immediate recall test (day 1), only the order of
the trials was again randomized. An identical trackball was in-
house adapted for MR compatibility and placed on the sub-
jects’ belly during scanning. Subjects again received a short
practice before the beginning of the task. The entire associa-
tive memory task was programmed and presented with pre-
sentation (Version 16.4, www.neurobs.com).
Working memory capacity
Previously, baseline catecholamine synthesis capacity was
shown to correlate with individual working memory capacity
(Cools et al. 2008; Landau et al. 2009) which is regarded as a
stable, trait-like measure (Ilkowska and Engle 2010; Engle
2010). We assessed working memory capacity using the
Dutch version of the Listening Span Task (Daneman and
Carpenter 1980). In this task, subjects listened to sets of 1–7
sentences (that is, 3 sets per working memory level 1–7). For
each sentence, a written factual verification question had to be
answered. After the last sentence of each set, subjects were
asked to turn the page and retrieve the final words of each
sentence in the order in which they were presented. The lis-
tening span, or working memory capacity, represents the max-
imum number of sentences that were answered correctly (i.e.,
correct factual verification and correctly retrieved final word
for all sentences in a set) on at least 2 out of 3 sets per working
memory level. The maximum score was 7. If 1 set (out of 3)
was answered correctly on the next highest working memory
level, then this was scored with 0.5 points extra. The task was
completed at the end of day 4 (∼25 min, outside the MR
scanner) since we wanted to avoid any interfering effects of
other tasks on associative memory encoding and consolida-
tion during day 1.
Study medication, randomization, and un-blinding
procedure
Subjects orally received one capsule of either 20 mg MPH
(Ritalin®) or placebo (lactose product) after the study phase
of the associative memory task (Materials and methods, Study
procedure). The assignment to MPH and placebo groups was
randomized in groups of 10 subjects and the subjects, as well
as the research team were blind to the randomization. Study
medication and randomization list were prepared by the
Department of Clinical Pharmacy (Radboud University
Medical Center, Nijmegen, The Netherlands). After inclusion
of all subjects, drug conditions were coded with A and B by an
independent researcher and the un-blinding was done after the
analysis of the critical outcome measures was finished (i.e.,
analysis of physiological and behavioral data).
Physiological and behavioral data analysis
Heart rate, blood pressure, and mood (PANAS) were mea-
sured 3 times throughout day 1 (Fig. 1a). Thesemeasures were
each analyzed using a mixed ANOVA with time (1–3) as a
within-, and drug (MPH, placebo) as a between-subjects fac-
tor. Memory performance was defined as the number of cor-
rect responses in the associative memory task (Materials and
methods, Associative memory task) for the study cycles (1–5,
day 1), the immediate recall test (day 1), and for the delayed
recall test (day 4). Performance and corresponding reaction
times (RTs) for correct responses from the study phase were
analyzed using mixed ANOVAs with Study Cycle (1–5) as a
within-, and Drug (MPH, placebo) as a between-subjects fac-
tor. Memory performance for correct responses from the recall
tests were analyzed using a time (immediate, delayed) × drug
(MPH, placebo) mixed ANOVA. For the delayed recall test,
only object-location associations that were retrieved correctly
at both the immediate and the delayed recall test were
regarded as Bcorrect^ (see also fMRI analyses below).
Corresponding RTs were analyzed using two independent-
samples t tests, since immediate and delayed recall tests were
performed in the behavioral laboratory and inside the MR
scanner, respectively, and are thus not directly comparable.
Subjects displayed very few responses that were incorrect at
the immediate but correct at the delayed recall test (Bforgotten-
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remember responses^; mean ± SEM: 2.9 ± 0.25 trials) and few
trials without any responses (Bmisses^; study, 2.9 ± 0.5 trials;
immediate recall test, 1.4 ± 0.2 trials; delayed recall test, 3.5 ±
0.4 trials). These trials were excluded from the behavioral
analysis, and were collapsed in a regressor of no interest for
fMRI analyses of the delayed recall test on day 4 (see below).
For all ANOVAs, we applied Greenhouse-Geisser correction
whenever the assumption of sphericity was violated and sig-
nificant interactions were followed up using independent-
samples t tests. Alpha was set to 0.05 throughout.
Additionally, we expected the effects of MPH administration
on physiological and behavioral outcome measures to be af-
fected by individual working memory capacity. We therefore
repeated the above analyses with working memory capacity
(mean centered) as a covariate.
Imaging parameters
Imaging data were acquired using a 3 TeslaMRI scanner (Skyra,
Siemens, Erlangen, Germany) using a 32-channel head coil. We
obtained 364 T2*-weighted BOLD images during the delayed
recall test (day 4). Parameters were as follows: gradient multi-
echo EPI sequence (Poser et al. 2006), TR = 2100ms, TEs = 8.5,
19.3, 30, 41 ms, flip angle = 90°, FOV= 224 × 224 mm, ma-
trix = 64 × 64, 34 ascending axial slices, 17% slice gap, voxel
size = 3 mm. Structural scans were acquired using a
Magnetization-Prepared Rapid Gradient Echo (MP-RAGE) se-
quence with the following parameters: TR = 2300 ms, TE =
3.03 ms, flip angle = 8°, FOV= 256 × 256 mm, voxel size =
1 mm isotropic.
MRI data preprocessing
All imaging data were analyzed using SPM8 (http://www.fil.ion.
ucl.ac.uk/spm/) in combinationwithMATLAB (MATLAB2014,
The Mathworks, Inc., Natick, MA, USA). First, echoes from the
four different echo timeswere combined into single volumes.We
used 32 scans that were acquired before the start of the delayed
recall test (∼1 min) to determine the optimal weighting of echo
times for each voxel. This was done by calculating the contrast-
to-noise ratio for each echo per scan. Images from multiple echo
times were then combined by performing motion correction on
the first echo, estimating iterative rigid body realignment to min-
imize the residual sum of squares between the first echo of the
first scan and all remaining scans. The estimated parameters were
then applied to all other echoes, realigning all echoes to the first
echo of the first scan. Finally, the calculated optimal echo time
weightings were used to combine the four echo images into a
single image. The structural scan was co-registered to the mean
functional scan. Next, using unified segmentation (Ashburner
and Friston 2005), the structural scan was segmented and the
normalization parameters were estimated using these normaliza-
tion parameters. All images (functional and structural) were
spatially normalized to the Montreal Neurological Institute
(MNI) EPI template and smoothed with a 3D Gaussian kernel
(8 mm full-width at half maximum, FWHM).
fMRI activation analysis
To investigate differential activation of MPH and placebo
groups during memory retrieval (delayed recall test, day 4),
we sorted trials based on individual memory performance and
grouped them in three regressors: First, correct trials were
defined as object-location associations that were correctly re-
membered at both the immediate recall test (day 1) and the
delayed recall test (day 4). Second, incorrect trials were de-
fined as object-location associations that were incorrectly re-
membered at the delayed recall test (day 4). Third, object-
location associations that were correctly remembered at the
delayed recall test (day 4) but incorrectly remembered at the
immediate recall test (day 1) were collapsed together with
misses (trials without any response) into a regressor of no
interest. The blood oxygen level-dependent (BOLD) response
for all trials was modeled with these separate task regressors,
time-locked to the onset of the trials. All events were estimat-
ed as a boxcar function with the duration of one trial (5.5 s)
and convolved with a canonical hemodynamic response func-
tion. Regressors for correct and incorrect responses were para-
metrically modulated with RTs. In addition, the six realign-
ment parameters were included in the design matrix, and a
high-pass filter with a cut-off at 128 s was applied. General
activation during the delayed test was assessed with a one-
sample t test of the contrast correct > incorrect. Retrieval-
related brain activity was compared between groups using
an independent-samples t test (correct > incorrect). Unless
stated otherwise, activation was tested for significance using
cluster inference with a cluster-defining threshold ofP < 0.005
and a cluster probability of P < 0.05 family-wise error (FWE)
corrected for multiple comparisons. Furthermore, we expected
that the effects of MPH administration on retrieval-related
brain activity would depend on individual differences in work-
ing memory capacity. This was investigated with an
independent-samples t test (correct > incorrect) and working
memory capacity was added as a covariate of interest.
fMRI connectivity analysis
As an exploratory step, we investigated connectivity during
memory retrieval (delayed recall test, day 4) and its associa-
tion with working memory capacity using psychophysiologi-
cal interaction analysis (PPI; Friston et al. 1997). Seed regions
were defined based on analyses of the association between
retrieval-related activation (correct > incorrect) and working
memory capacity, separately for each group (two one-sample
t tests; Results, Activation and connectivity during memory
retrieval 72 h after drug intake depend on working memory
662 Psychopharmacology (2017) 234:657–669
capacity; see also Table 2). For the placebo group, we placed a
seed in the left lateral occipital cortex (x = −52, y = −63, z = 0;
8 mm sphere around peak coordinate). For the MPH group, a
seed in the right postcentral gyrus was used (x = 66, y = −14,
z = 18; 8 mm sphere around peak coordinate). For each seed,
the first eigenvector of the time course was extracted (i.e., the
physiological factor) and adjusted for average activation dur-
ing the task (F-contrast). This time course was then convolved
with the respective task condition (i.e., the psychological fac-
tor; contrast correct > incorrect) and increased connectivity
with the seed region during correct > incorrect retrieval was
investigated. The resulting individual PPI contrast images for
each seed region were submitted to one-sample t tests per drug
condition (MPH, placebo), and working memory capacity
was added as a covariate of interest (see above). Again, unless
stated otherwise, significance was tested using cluster infer-
ence with a cluster-defining threshold of P < 0.005 and a clus-
ter probability of P < 0.05 FWE-corrected for multiple
comparisons.
Scan-to-scan motion between groups
Finally, we assured that our fMRI results were not confounded
by unequal magnitude of scan-to-scan motion between the
two groups during memory recall. We calculated the
framewise displacement (FD) for every scan at time t by
FD(t) = |Δdx(t)| + |Δdy(t)| + |Δdz(t)| + r|α(t)| + r|β(t)| + r|γ(t)|,
where (dx, dy, dz) is the translational and (α, β, γ) the rota-
tional movement (Power et al. 2012). The average FD during
memory recall was generally small (mean ± SEM,MPH: 0.13
± 0.01 mm; placebo: 0.13 ± 0.01 mm) and did not significant-
ly differ between groups (P = 0.703). Thus, the amount of
movement during the delayed recall was comparable between
subjects who had received MPH or placebo.
Results
Subject sample
From our final sample of 53 subjects, 26 subjects received
20 mg MPH (mean = 24 years, age range = 18–31 years) and
27 subjects received placebo (mean = 23 years, age range =
19–29 years) at t = 0 min (Fig. 1a). Within the MPH group, 14
out of 26 subjects (54%) correctly guessed that they had re-
ceived MPH with a certainty of 66%. Twenty-four out of 27
subjects (89%) correctly guessed that they had received pla-
cebo with a certainty of 73%.
Several self-report questionnaires were completed at base-
line on day 1 (Materials and methods, Study procedure). The
groups did not significantly differ in behavioral inhibition
(BIS; mean ± SEM, MPH: 17.8 ± 3, placebo: 17.7 ± 3.4, P =
0.908), but the MPH group reported increased behavioral
activation (BAS; MPH: 25 ± 4.1, placebo: 22.9 ± 3.2, P =
0.045; not significant using a Bonferroni alpha of 0.008).
There was no significant difference in trait impulsivity be-
tween groups (Barratt Impulsiveness Scale; MPH: 63 ± 9.5,
placebo: 65.6 ± 9.6, P = 0.330). Further, there was no signifi-
cant group difference in ADHD symptoms of inattention
(ADHD Rating Scale-IV; MPH: 19 ± 4.3, placebo: 20 ± 5.6,
P = 0.489) or impulsivity (MPH: 4.5 ± 1.2, placebo: 5.2 ± 1.6,
P = 0.086), but placebo subjects reported more symptoms of
hyperactivity (MPH: 15 ± 3.1, placebo: 16.8 ± 3, P = 0.043;
not significant using a Bonferroni alpha of 0.008). However,
there was no reliable relation between any of the above mea-
sures with associative memory performance on day 4 (Results,
Associative memory performance; all P > 0.05). Further,
MPH and placebo groups did not differ significantly in terms
of workingmemory capacity (Listening Span Task;MPH: 4.7
± 1.2, placebo: 5.2 ± 0.9, P = 0.102).
Physiological and psychological effects of drug
administration
To start out, we investigated the effects of drug administration
on heart rate, blood pressure, and mood (PANAS) on day 1.
We found a decrease in heart rate across day 1 (main effect of
time: F(1.8,91.4) = 69, P < 0.0005) and a time × drug interac-
tion (F(1.8,91.4) = 6.3, P = 0.004; no main effect of drug: P =
0.058). This was caused by an increase (or less of a decrease)
in heart rate of the MPH group at t = 230 min after drug intake
(t(37.5) = −2.9, P = 0.005). There was no significant differ-
ence in heart rate between MPH and placebo groups at t =
−45 min before drug intake (P = 0.825) and a trend-level in-
crease (or less of a decrease) at t = 110 min after drug intake
for subjects who received MPH (t(47.3) = −1.9, P = 0.066;
Fig. 2a, left upper panel).
Systolic blood pressure was higher in the MPH group
(main effect of drug: F(1,51) = 20.5, P < 0.0005) but did
not depend on or significantly interact with the drug ma-
nipulation (no main effect of time: P = 0.077; no time ×
drug interaction: P = 0.721). Similarly, we found higher
diastolic blood pressure for the MPH group (main effect
of drug: F(1,51) = 7.5, P = 0.008), but again unrelated to
the drug manipulation (no main effect of time: P = 0.282;
no time × drug interaction: P = 0.471; Fig. 2a, lower
panels).
Positive mood did not differ systematically between the
two groups but showed a general decrease over the course of
day 1 (main effect of time: F(1.7,84.5) = 15, P < 0.0005, no
main effect of drug: P = 0.541; interaction time × drug:
F(1.7,84.5) = 4, P = 0.030), as did negative mood (main effect
of time: F(2,102) = 10.6, P < 0.0005, no main effect of drug:
P = 0.532; interaction time × drug: F(2,102) = 3.3, P = 0.042;
post hoc comparisons at t = −45 min, P = 0.199; at t =
110 min, P = 0.633; at t = 230 min, P = 0.367; Fig. 2a, right
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upper panel). Results for heart rate, blood pressure, and mood
did not change when we repeated the analyses with working
memory capacity as a covariate.
In sum, the MPH group (compared to the placebo group)
exhibited less of a decrease in heart rate after drug intake on
day 1. Blood pressure was generally higher in theMPH group.
Positive and negative mood ratings decreased throughout day
1 in both groups. Both, blood pressure and mood, were unaf-
fected by the drug manipulation.
Drug effects on associative memory performance
Associative memory performance was defined as the number
of correctly remembered object-location associations.
Subjects showed an increase in performance over the study
cycles on day 1 (main effect of time: F(1.8, 91.6) = 352.3,
P < 0.0005; Fig. 2b, left upper panel). As expected, this in-
crease did not differ significantly between groups (no main
effect of drug: P = 0.304; no time × drug interaction: P =
0.201), since the drug was administered after the completion
of the study phase (Materials and methods, Procedure;
Fig. 1a). Also, RTs for correct responses did not significantly
differ between the two groups and showed a general decrease
across study cycles (main effect of time: F(2.8,137.6) = 20.5,
P < 0.0005; no main effect of drug: P = 0.461; no time × drug
interaction: P = 0.831; Fig. 2b, left lower panel).
After study, subjects received an oral dose of either 20 mg
MPH or placebo and subsequently performed the immediate
recall test (day 1). Seventy-two hours later, subjects performed
the delayed recall test (Materials and methods, Procedure).
Memory performance decreased over the course of 72 h (main
effect of time:F(1,51) = 374.9, P < 0.0005), but this decrease did
not significantly differ between theMPH and placebo groups (no
main effect of drug: P = 0.389; no time × drug interaction: P =
0.212; Fig. 2b, right upper panel). Comparably, RTs for correct
responses at the immediate and delayed recall tests did not sig-
nificantly differ between MPH and placebo groups (immediate
recall test: P = 0.874; delayed recall test: P = 0.727; Fig. 2b, right
lower panel). Results remained stable when we re-analyzed as-
sociative memory performance and RTs with individual working
memory capacity as a covariate.
In conclusion, both groups showed a steady increase in asso-
ciative memory performance throughout the study cycles on day
1, parallelized by a decrease in RTs for correct responses. Also,
performance at the immediate recall test (day 1) was high and did
not differ between groups. Contrary to what we expected, the
MPH group did not show better memory performance after 72 h.
Activation during memory retrieval 72 h after drug intake
To verify that correct memory retrieval was associated with
reliable, neocortical engagement on day 4, we first investigated
activation collapsed across both groups. Overall, we found in-
creased activation in the hippocampus and surrounding MTL
structures, medial prefrontal and posterior cingulate cortex, an-
gular gyrus, striatum, middle and inferior temporal structures,
including the fusiform gyrus and the lateral occipital cortex
during correct > incorrect memory retrieval (Fig. 3, Table 1).
Next, we hypothesized that the MPH compared to the placebo
group would show stronger engagement of neocortical regions
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during correct memory retrieval on day 4, including the medial
prefrontal and posterior cingulate cortex, as well as the angular
gyrus and posterior representational areas. However, we did not
find differential activation between the MPH and placebo
group, also not at a more liberal threshold (P < 0.005,
uncorrected; contrasts MPH > placebo, placebo > MPH).
Thus, correct (compared to incorrect) retrieval yielded stronger
activation in the hippocampus and neocortical regions that did
not significantly differ between groups.
Activation and connectivity during memory retrieval 72 h
after drug intake depends on working memory capacity
Lastly, we hypothesized that the effects of drug administration on
retrieval-related activation would linearly depend on individual
variation inworkingmemory capacity, a proxymeasure for base-
line catecholamine synthesis capacity. We found that working
memory capacity was associated with increased activation in
the left lateral occipital cortex, fusiform gyrus, left angular gyrus,
and the right postcentral gyrus during correct relative to incorrect
retrieval inMPH compared to placebo subjects (MPH> placebo,
no difference for placebo >MPH; correct > incorrect; Fig. 4a,
Table 2). Hence, the linear relationship between retrieval-
related activation and individual working memory capacity dif-
fered between groups. To follow-up on this, we tested the asso-
ciation between individual working memory capacity and
retrieval-related activation separately for each group using one-
sample t tests, again with working memory capacity added as a
covariate of interest. In the placebo group, increased activation in
left fusiform gyrus and lateral occipital cortex during correct >
incorrect retrieval was negatively associated with working mem-
ory capacity (Fig. 4b, Table 2). Conversely, in the MPH group,
increased activation in the right postcentral gyrus during correct >
incorrect retrieval was positively associated with working mem-
ory capacity (Fig. 4c, Table 2).
In addition to levels of activation, drug administration might
differentially affect retrieval-related connectivity depending on
individual working memory capacity. Thus, we performed con-
nectivity analyses (PPI) and placed seeds in the left lateral oc-
cipital cortex for placebo subjects and in the right postcentral
gyrus for MPH subjects (see above, andMaterials and methods,
fMRI connectivity analysis). Results revealed increased func-
tional coupling between the left lateral occipital cortex and the
right hippocampus (and surrounding medial temporal lobe
structures) during correct compared to incorrect retrieval to be
positively associated with working memory capacity in the pla-
cebo group (Fig. 5, Table 2). There was no negative relationship
with working memory capacity. Also, there was no significant
association between connectivity profiles of the right postcentral
gyrus and working memory capacity in the MPH group.
In sum, the relationship of working memory capacity
with activation and connectivity during correct retrieval dif-
fered between the groups. In the placebo group, correct
memory retrieval was associated with increased activation
in the left lateral occipital cortex and fusiform gyrus, as well
as decreased connectivity between the left occipital cortex
and the hippocampus at lower working memory capacity. In
the MPH group, correct memory retrieval was associated
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z = -16
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t-value
0 10
correct > incorrect
Fig. 3 Activation during memory retrieval 72 h after drug intake.
Increased BOLD activation across all subjects (both groups; N = 53)
during memory retrieval of correct compared to incorrect
object-location associations on day 4. Results are shown at P < 0.05
FWE-corrected (Table 1). Sliced images are based on the average
structural scan of all subjects. L left
Table 1 Activation during memory retrieval 72 h after drug intake
MNI
Contrast and brain regions x y z Z value Cluster size
All subjects, N = 53
Correct > incorrect
L middle temporal gyrus −46 −52 4 4692
L cuneus 0 −88 24 6.76 462
L superior frontal gyrus −14 46 46 6.58 1693
R cingulate gyrus 4 −21 42 6.37 182
R inferior frontal gyrus 49 38 4 6.27 44
R precentral gyrus 42 −10 63 5.79 24
R middle frontal gyrus 32 63 −7 5.66 19
L middle frontal gyrus −38 24 46 5.56 33
L inferior frontal gyrus −32 49 −10 5.41 9
R inferior temporal gyrus 49 −7 −35 5.37 14
MNI coordinates represent the location of peak voxels. We report the first
local maximum within each cluster. Effects were thresholded at P < 0.05,
FWE-corrected for multiple comparisons. Anatomical nomenclature was
obtained from the Laboratory for Neuro Imaging (LONI) Brain Atlas
(LPBA40; http://www.loni.usc.edu/atlases/)
L left, R right
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with increased activation in the postcentral gyrus at higher
working memory capacity.
Discussion
The present study investigated the effects of catechol-
aminergic modulation on the synaptic and subsequent
systems consolidation of associative memories in humans.
Contrary to what we expected, MPH administration after
learning did not facilitate long-term associative memory
compared to placebo. Also, there was no significant group
difference in activation during delayed memory retrieval
after 72 h. However, we found that the effect of drug
administration on subsequent retrieval-related activation
correct > incorrect
covariate working memory capacity
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Fig. 4 Activation duringmemory retrieval 72 h after drug intake depends
on working memory capacity. a The relationship between correct >
incorrect retrieval-related BOLD activation and individual working
memory capacity is different for the methylphenidate (MPH) and placebo
groups. b–cUpper panels: the significant effects from awere followed up
with one-sample t tests for each group, for the contrast correct > incorrect,
and again with working memory capacity added as a covariate of interest.
b Increased activation during memory retrieval in placebo subjects
(N = 27) is related to lower working memory capacity. c Increased
activation during memory retrieval in MPH subjects (N = 26) is related
to higher working memory capacity. For visualization purposes, left and
right lower panels show the relationship between working memory
capacity and the % signal change during correct > incorrect retrieval
(arbitrary units, a.u.), extracted from the significant clusters. Results are
shown at P < 0.005 (P < 0.05, FWE-corrected at cluster level; see also
Table 2). Sliced images are based on the average structural scan of all
subjects. L left
Table 2 Activation and connectivity duringmemory retrieval 72 h after
drug intake depends on working memory capacity (WMC)
MNI
Contrasts and brain regions x y z Z value Cluster
size
All subjects, N = 53
Correct > incorrect, MPH > placebo, × WMC
L lateral occipital cortex −52 −66 −4 4.23 739
R middle occipital gyrus 28 −80 0 4.14 177
L superior parietal gyrus −32 −63 56 4 117
R postcentral gyrus 66 −10 18 3.78 131
R inferior occipital gyrus 35 −66 −18 3.17 133
Placebo subjects, N = 27
Correct > incorrect, × WMC N
L lateral occipital cortex −52 −63 0 3.68 125
L fusiform gyrus −32 −60 −18 3.58 218
MPH subjects, N = 26
Correct > incorrect, × WMC P
R postcentral gyrus 66 −14 18 3.44 179
Placebo subjects, N = 27
PPI, Correct > incorrect, × WMC P
R middle temporal gyrus 60 10 −24 3.92 153
R superior temporal gyrus 49 14 −21 3.38
R hippocampus 28 −10 −24 3.34
R middle temporal gyrus 66 0 −21 3.24
R hippocampus 18 0 −24 3.14
MNI coordinates represent the location of peak voxels. We report the first
local maximum within each cluster. For the connectivity result (PPI,
lower part), we report the first five local maxima within the cluster.
Effects were tested for significance using cluster inference with a
cluster-defining threshold of P < 0.005 and a cluster probability of
P < 0.05 FWE-corrected for multiple comparisons (critical cluster sizes:
all subjects, 93 voxels; placebo subjects, 89 voxels; methylphenidate
(MPH) subjects, 108 voxels; placebo subjects, PPI, 110 voxels). Results
from the upper analysis (all subjects, N = 53, correct > incorrect, MPH >
placebo, × WMC) remain widely consistent using a cluster-defining
threshold of P < 0.001: L middle temporal gyrus, x = −52, y = −66,
z = −4, Z value = 4.23, cluster size: 64 voxels; L middle occipital gyrus,
x = −28, y = −91, z = 21, Z value = 4.06, cluster size: 70 voxels; L inferior
occipital gyrus, x = −21, y = −77, z = −7, Z value = 3.91, cluster size: 85
voxels. Results from the remaining analyses are not significant at a
cluster-defining threshold of P < 0.001. The PPI was based on a spherical
seed region in the lateral occipital cortex (x = −52, y = −63, z = 0; see also
Materials and methods, fMRI connectivity analysis). N denotes a
negative, and P a positive association between outcome and working
memory capacity. Anatomical nomenclature was obtained from the
Laboratory for Neuro Imaging (LONI) Brain Atlas (LPBA40;
http://www.loni.usc.edu/atlases/)
L left, R right
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and connectivity was dependent on individual variations
in working memory capacity.
We expected that the up-regulation of catecholaminer-
gic signaling during early consolidation would stabilize
initially fragile memories that would otherwise decay
and thus lead to enhanced long-term associative memory
performance following MPH compared to placebo admin-
istration. This would provide evidence for a synaptic tag-
ging and capture mechanism in humans. Contrary to our
expectations, we did not find increased associative mem-
ory performance for the MPH relative to the placebo
group after 72 h (Fig. 2). There are several possible ex-
planations for this null finding. First, MPH administration
might have been efficient but was masked by other exper-
imental factors. For instance, receiving a pill, even if it
only was a placebo, could have been sufficiently arousing
to facilitate the release of endogenous catecholamines and
to foster synaptic consolidation. Second, the dosage of
20 mg MPH might not have been sufficient to facilitate
catecholaminergic signaling in order to augment synaptic
consolidation after learning. Although we chose the abso-
lute dose of 20 mg MPH in accordance with previous
studies (Izquierdo et al. 2008; Linssen et al. 2012), the
average relative body-weight-adjusted dose of 0.27 mg/
kg MPH was rather low, compared to the dose typically
used to investigate the effects of MPH on brain function
(∼0.8 mg/kg; Volkow et al. 2001). Nevertheless, MPH
administration affected heart rate (Fig. 2) but did not sig-
nificantly affect blood pressure or mood (see also Volkow
et al. 2002). Third, the timing of drug administration was
perhaps not optimal to facilitate synaptic consolidation,
and catecholamine levels could have peaked earlier (e.g.,
after the first study cycle) or later (Izquierdo et al. 2008).
Further research is needed to clarify these points.
Next, we hypothesized that synaptic consolidation
would pave the way for the subsequent neocortical stabi-
lization of memory traces (Frey and Morris 1997;
Frankland and Bontempi 2005; Lesburguères et al.
2011). As expected, results revealed stronger activation
in the medial prefrontal and posterior cingulate cortex,
the angular gyrus, and posterior representational regions
but also in the hippocampus, during correct relative to
incorrect memory retrieval after 72 h (Fig. 3). However,
we did not find increased engagement of neocortical re-
gions in subjects who received MPH compared to place-
bo. Notably, there was no disengagement of the hippo-
campus during the delayed retrieval which is probably
due to the spatial associative nature of our task (Burgess
et al. 2001; Düzel et al. 2003; Mayes et al. 2007).
Although catecholamine administration during early
consolidation did not foster long-term associative memory
performance, we found that the effects of MPH on
retrieval-related neuronal processes were dependent on in-
dividual variations in working memory capacity, a proxy
measure for baseline catecholamine synthesis capacity
(Cools et al. 2008; Landau et al. 2009). Subjects who re-
ceived placebo showed increased activation in the left lat-
eral occipital and fusiform regions but decreased connec-
tivity between the left lateral occipital cortex and the right
hippocampus at lower working memory capacity during
correct over incorrect retrieval (Figs. 4 and 5). Conversely,
for subjects who received MPH, increased activation in the
right postcentral gyrus was associated with higher working
memory capacity (Fig. 4). Behaviorally, we did not find an
interaction betweenworkingmemory capacity and associative
memory performance.
Prior studies have shown that inter-individual differences
in drug response can be explained by working memory capac-
ity (Kimberg et al. 1997; Mehta et al. 2000; van der Schaaf
et al. 2013). While cognitive performance in subjects with low
working memory capacity typically benefits from administra-
tion of catecholaminergic stimulants (Mehta et al. 2000; Gibbs
and D’Esposito 2005), they can have detrimental effects in
subjects with high working memory capacity (Kimberg et al.
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Fig. 5 Connectivity during memory retrieval 72 h after drug intake
depends on working memory capacity. Placebo subjects (N = 27) show
increased connectivity (PPI) during correct > incorrect retrieval between
the left lateral occipital cortex (LOC; 8 mm sphere around peak
coordinate: x = −52, y = −63, z = 0; marked as filled white circle;
Materials and methods, fMRI connectivity analysis) and the right
hippocampus, including surrounding medial temporal (MTL) structures,
at higher working memory capacity. Connectivity is schematically
illustrated through the dashed line. For visualization purposes, the scatter
plot shows the relationship between working memory capacity and
LOC-hippocampal/MTL connectivity during correct > incorrect retrieval
(% signal change, arbitrary units, a.u.), extracted from the significant
cluster. Results are shown at P < 0.005 (P < 0.05, FWE-corrected at
cluster level; see also Table 2). Sliced images are based on the average
structural scan of all subjects. L left
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1997). This speaks for an inverted u-shaped relationship
(Williams and Goldman-Rakic 1995; Cools and D’Esposito
2011). Here, we suggest that subjects with low working mem-
ory capacity fall on the left-hand side of the inverted u-shaped
curve, and subjects that score high are located in the middle
(i.e., optimal baseline catecholamine synthesis capacity).
Although higher working memory capacity was not associat-
ed with better long-term memory performance, it was related
to enhanced connectivity between the left lateral occipital cor-
tex and the hippocampus but decreased activation in lateral
occipital cortex and fusiform gyrus during correct memory
retrieval in subjects who received placebo. Presumably, in-
creased cross-talk reflects better integration of mnemonic fea-
tures into a conjunctive, episodic-like memory representation
and memory stabilization within an extended hippocampal-
neocortical network. This might indicate more efficient neu-
ronal processing (Gibbs and D’Esposito 2005; Rypma et al.
2006). Therefore, subjects with high working memory capac-
ity might already display optimal grounds for synaptic and
subsequent systems consolidation. Furthermore, an additional
dose of MPH should be detrimental rather than beneficial for
neuronal processing in subjects with already optimal baseline
catecholamine levels. Indeed, for subjects who receivedMPH,
higher working memory capacity was associated with in-
creased activation in the right postcentral gyrus. Our results
thus imply thatMPH administration affected the consolidation
of long-term memory traces depending on baseline catechol-
amine levels. This lead to differential retrieval processes for
correct, associative memories after 72 h. One possible limita-
tion is that our between-subject design might have reduced the
sensitivity of our baseline-dependent analysis. A follow-up
study may employ a within-subject manipulation to disentan-
gle the effects of MPH from subject-specific variance.
Overall, we did not find evidence for increased long-
term associative memory performance in MPH compared
to placebo subjects, and groups did not show differential
activation during memory retrieval after 72 h. However,
these results do not preclude the presence of a synaptic
tagging and capture mechanism in humans. Most impor-
tantly, we found that MPH administration after learning
affected long-term retrieval-related neural processes
depending on individual differences in catecholamine
synthesis capacity at baseline.
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